Dynavax Technologies Corporation logo DVAX - Dynavax Technologies Corporation

Inactive Ticker DVAX is not actively trading. Quotes and analytics may be stale.
Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 9
HOLD 1
SELL 1
STRONG
SELL
0
| PRICE TARGET: $27.00 DETAILS
HIGH: $32.00
LOW: $20.00
MEDIAN: $29.00
CONSENSUS: $27.00
UPSIDE: 74.19%
AlphaVal

AlphaVal

Deterministic, archetype-aware fair value

Platform & Compounding FCF 85% confidence

Primary model: Two-stage FCF DCF

Valuation Signal Overvalued Mild
Trading 8.3% above fair value
Current Price $15.50
Bear Case $9.61 38.0% downside ($9.61 - $15.50) / $15.50 = -38.0% 12% stage 1 growth, 11% discount
Fair Value $14.32 7.6% downside ($14.32 - $15.50) / $15.50 = -7.6% 20% stage 1 growth, 11% discount
Bull Case $20.23 30.5% upside ($20.23 - $15.50) / $15.50 = 30.5% 26% stage 1 growth, 11% discount

Adjust Assumptions

20.0%
11.0%
3.0%

Key Value Driver

FCF growth rate (20% base case)

Terminal Value % of EV 46%
Implied Market Multiple 50.9x
Market is pricing in (growth) 21.4% vs our 20.0% base

Plain-Language Summary

Using a two-stage FCF DCF with 20% growth decelerating over 15 years, discounted at 11%, the base-case intrinsic value is $14.32 per share.

Analyst Consensus (External Reference)

Never blended into the bear/base/bull estimates above -- shown only as an outside comparison.

Average Target (11 analysts) $27.00
Analyst Range $20.00 – $32.00
Divergence from AlphaVal 47%

Warnings

Stock-based employee pay equals 193% of profits. This dilutes existing shareholders, so cash flow alone overstates what owners really earn.
Wall Street's average price target is $27.00 (from 11 analysts). Our estimate is 47% below the consensus -- consider that gap carefully.

Key Risks

  • P/E alone misleads — earnings depressed by growth investment
  • Cyclical or commodity businesses may be misclassified as platforms
  • Terminal value dominance suggests sensitivity to long-run assumptions